ContextVision enters Data Quality market with organ-specific enhancements
Stockholm, Sweden, July 18, 2024 – ContextVision, a leading provider of medical image processing and analysis technology, is excited to announce a strategic evolution of its Image Quality business. In response to the rapidly advancing digital transformation in healthcare, ContextVision is expanding its product pipeline into Data Quality, preparing to establish vital clinical and commercial partnerships.
Expanding product pipeline from Image Quality to Data Quality
ContextVision is committed to expanding its Image Quality business, which today focuses on enhancing medical image quality for a radiologists’ interpretation. Alongside, ContextVision is pioneering a new Data Quality business aimed at machine-aided interpretation. Data Quality is a natural extension of ContextVision’s Image Quality business that aims to build organ-specific applications. This new product pipeline will improve physiological quantification from imaging modalities, enabling the implementation of digital biomarkers. By facilitating both a better interpretation and quantification of physiological findings from medical imaging, ContextVision’s innovative products will provide powerful tools to our customer’s diagnostic solutions.
Focusing on organ-specific enhancements for improved disease management
Leveraging decades of expertise in image processing, such as resizing, de-noising and segmentation, ContextVision is now targeting organ-specific image enhancements to streamline disease management. These advancements will enable higher performance for AI/Machine Learning algorithms and clinical-decision support applications, especially for near-patient imaging. By enhancing specific organ imaging, ContextVision will support its customers in delivering faster and more definitive diagnosis with Point-of-Care Ultrasound solutions.
"Our new Data Quality business with the development of organ-specific imaging solutions underscores our dedication to pushing the boundaries of medical technology. By integrating these advancements, we aim to deliver unparalleled precision in diagnostics. We are now in the final stages of signing new clinical and commercial partnerships which will lay a strong foundation for what lies ahead in our expanded product offering. It is immensely gratifying to be contributing to such significant advancements in global healthcare", says Gerald Pötzsch, CEO of ContextVision.
Strategic growth and expansion
With an ambitious vision for the future, ContextVision is poised to embark on a growth trajectory fueled by organic growth and potentially supported by inorganic opportunities. The company is looking into different strategic options, particularly focused on expanding its capabilities in acquisition intelligence, and thereby, optimizing imaging parameters for specific modalities earlier in the imaging chain. This will enable customers to optimize the final output of their imaging products through corrective actions or enhancements during the initial stages of image formation.
For more information, please contact:
[email protected]
About ContextVision
ContextVision is a medical technology software company specialized in image analysis and artificial intelligence. As the global market leader within image enhancement, we are a trusted partner to leading manufacturers of ultrasound, X-ray and MRI equipment around the world. Our expertise is to develop powerful software products, based on proprietary technology and artificial intelligence for image-based applications. Our cutting-edge technology helps clinicians accurately interpret medical images, a crucial foundation for better diagnosis and treatment. The company, established in 1983, is based in Sweden with local representation in the U.S., Japan, China and Korea. ContextVision is listed on the Oslo Stock Exchange under the ticker CONTX.